RG
EIDX

Redmile Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Redmile Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-452,295
Closed -$59.5M – 104
2020
Q4 		$59.5M Sell
452,295
-13,910
-3% -$1.23M 0.72% 42
2020
Q3 		$23.6M Sell
466,205
-127,637
-21% -$5.74M 0.43% 54
2020
Q2 		$28.3M Sell
593,842
-95,636
-14% -$4.45M 0.52% 49
2020
Q1 		$33.8M Sell
689,478
-11,700
-2% -$596K 0.95% 34
2019
Q4 		$40.2M Sell
701,178
-221,825
-24% -$11M 0.96% 30
2019
Q3 		$33.2M Buy
923,003
+44,600
+5% +$1.74M 1.11% 28
2019
Q2 		$27.3M Buy
878,403
+26,503
+3% +$718K 0.77% 39
2019
Q1 		$20M Sell
851,900
-1,600
-0.2% -$25.7K 0.58% 45
2018
Q4 		$11.7M Sell
853,500
-14,200
-2% -$179K 0.47% 48
2018
Q3 		$8.66M Buy
867,700
+676,700
+354% +$11.1M 0.27% 60
2018
Q2 		$3.88M Buy
+191,000
New +$4M 0.13% 63

Redmile Group's EIDX Position: Q1 2021 in Review

Redmile Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 452,295 shares — an estimated $59.5M sold.

Redmile Group first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $59.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Redmile Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Redmile Group sold 452,295 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $59.5M.
  • Redmile Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
  • Redmile Group's Eidos Therapeutics, Inc. Common Stock position peaked at $59.5M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Redmile Group's 13F filing for Q1 2021, filed 17 May 2021.